Tumour budding: a promising parameter in colorectal cancer

摘要: In 2011, the Tumour Node Metastasis (TNM) staging system still remains gold standard for stratifying colorectal cancer (CRC) patients into prognostic subgroups, and is considered a solid basis treatment management. Nevertheless, there challenge with regard to therapeutic strategy; stage II are not typically selected postoperative adjuvant chemotherapy, although some have comparable outcome III who, themselves do receive such treatment. Consequently, has been an inundation of 'prognostic biomarker' studies aiming improve stratification power TNM system. Most proposed biomarkers implemented because lack reproducibility, validation standardisation. This problem can be partially resolved by following REMARK guidelines. search novel factors CRC, one might glance at table in book entitled 'Prognostic Factors Cancer' published International Union against Cancer (UICC) 2006, which stage, L V classifications 'essential' factors, whereas tumour grade, perineural invasion, budding tumour-border configuration among others as 'additional' factors. Histopathology reports normally include features accompanied histological subtype information on but interestingly, (i.e., growth pattern) especially rarely reported. Although scoring systems 'BRE' breast 'Gleason' prostate solidly based histomorphological used daily practice, no additional complement available CRC. Regardless differences study design methods tumour-budding assessment, confirmed dozens groups worldwide, suggesting that may valuable candidate inclusion future mini-review therefore attempts present short concise overview budding, including morphological, molecular aspects underlining its inter-disciplinary relevance.